SNCA and Parkinson disease: CDNF was recently shown to interact directly with alpha-synuclein (αSyn), a major protein of Lewy bodies characteristic for the neuropathology of PD, decreasing αSyn cell entry and reducing αSyn phosphorylation, as well improving locomotor activity in a rodent αSyn model of PD [37].